Kornimate/medical-research-clean huggingface dataset:
efficacy of heat-shock protein (hsp) inhibitors in myeloproliferative syndromes (mps)

Conditions: Myeloproliferative Syndrome

Summary: heat-shock proteins (hsp) have been very highly conserved throughout the evolution of species and are characterized by their chaperone function, thanks to their ability to prevent aggregation and to promote the renaturation/break down of damaged proteins. among other targets, they also chaperone jak2, a key step that is deregulated in signalling in myeloproliferative syndromes (mps) because of the jak2v617f mutation. these hsp also have a potent cytoprotective action through their multiples inhibiting effects on apoptotic processes. little is known about levels of hsp expression, in particular for hsp70 and hsp27, in mps cells. however, in vitro studies of different cell models have shown the interest of hsp90 inhibitors in slowing cell proliferation in mps. these results have been confirmed in animal models with results in terms of blood counts and overall survival. in addition, it seems that the v617f mutated form of jak2 is more sensitive than the wild-type to hsp90 inhibitors. finally, inhibitors of hsp90 remain efficacious with regard to the inhibition of cell growth, even in cases of resistance to jak2 inhibitors. nonetheless, hsp90 inhibitors are known to stimulate the expression of other hsp, notably hsp27 and hsp70, which are, through their properties, tumorigenic and could lead to an escape phenomenon. thus the combined use of several hsp inhibitors could be beneficial, and eventually present synergistic effects on the inhibition of tumour processes.


Eligibility criteria:
inclusion criteria: mps patients: * patients with mps * patients who have been informed and not objected to the tests * patients over 18 years old * patients whose samples have been preserved at the crb in the "haemopathies" collection control patients: * patients over 18 years old * pregnant patients * patients who have been informed and not objected to the collection of their cord blood after the delivery exclusion criteria: * adults under guardianship
pomegranate consumption by poly-medicated metabolic syndrome patients

Conditions: Metabolic Syndrome

Summary: the objective is to evaluate whether the medication in polymedicated metabolic syndrome patients could determine the effects of a pomegranate extract on i) metabolic markers, ii) inflammatory markers, and iii) the modulation of the gut microbiota.


Eligibility criteria:
inclusion criteria: * body mass index \>30 kg/m2 or waist circumference \>94/80 cm (males/females) in european-caucasians subjects, plus two of the following: * triglycerides \>150 mg/dl or under treatment against hypertrigliceridemia. * fasting glucose ≥100 mg/dl * diagnosed type 2 diabetes mellitus * hdl-cholesterol (mg/dl) \<40/50 (males/females) or under treatment against low hdlc values. * systolic blood pressure \>130 mmhg o diastolic blood pressure \>85 mmhg, or under anti-hypertensive drug treatment. exclusion criteria: * age under 18 years * pregnancy or breastfeeding * antibiotic treatment within one month before inclusion in the trial * pomegranate allergy or intolerance (known or suspected) * chronic intestinal inflammatory diseases (ulcerative colitis, crohn's disease, etc.) * malignancies * consumption of botanicals or dietary supplements within one month before the inclusion and during the trial. * consumption of ellagitannin-rich sources within one week before the inclusion and during the trial (pomegranate, walnuts, strawberries, raspberries, tea, blackberries and oak-aged wine).

Keywords: metabolic syndrome pomegranate gut microbiota polyphenol polymedication inflammation obesity diabetes hypertension hyperlipidemia urolithins
a randomized, placebo-controlled, double-blind study of klh-2109 in patients with endometriosis (2)

Conditions: Endometriosis

Summary: the purpose of this study is to evaluate the efficacy and safety of klh-2109 in patients with endometriosis.


Eligibility criteria:
inclusion criteria: * female patients with endometriosis exclusion criteria: * patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Keywords: gonadotropin-releasing hormone (gnrh) antagonist
efficacy of eductyl® versus placebo for treatment of dyschesia

Conditions: Dyschesia

Summary: the purpose of this study is to assess the efficacy of eductyl versus placebo for treatment of patients with dyschesia treated by rectal rehabilitation.


Eligibility criteria:
inclusion criteria: * male or female over 18 years * patients with dyschesia * prescription of rehabilitation for dyschesia exclusion criteria: * rectal diseases * pain killers * pregnant women * breast feeding patients * non-compliant patients

Keywords: dyschesia treatment rehabilitation dyschesia
an exploratory study of ds-8500a on beta cell function using hyperglycemic clamp

Conditions: Type 2 Diabetes Mellitus

Summary: the objective of the study is to evaluate change in insulin secretory capacity in patients with type 2 diabetes mellitus as determined by hyperglycemic clamp after a 28-day oral administration of ds-8500a at 75 mg in a placebo-controlled, 2 × 2 crossover study. in addition, safety of this regimen will be examined in this study.


Eligibility criteria:
inclusion criteria: * patients aged ≥ 20 years at the time of informed consent * japanese patients with type 2 diabetes * patients who have hba1c ≥ 7.0% and \< 9.0% exclusion criteria: * patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or ketoacidosis * patients receiving or requiring treatment with insulin * patients with a body mass index (bmi) of \< 18.5 kg/m2 or ≥ 35.0 kg/m2 * patients with clinically evident renal impairment (estimated glomerular filtration rate \[egfr\] of \< 45 ml/min per 1.73 m2) or clinically significant renal disease * patients with fasting plasma glucose ≥ 240 mg/dl

Keywords: type 2 diabetes mellitus adult developmental phase ii
comparing patient satisfaction & stress distribution on mandibular ridge by three posterior occlusal scheme in complete denture

Conditions: Edentulous

Summary: in this randomized clinical trial to compare the patients' satisfaction of complete dentures with different occlusal forms, after simple randomized sampling of 15 participant that will be signed informed consent and their latest teeth was extracted 3 month ago, will be selected. for each participant, it will be made 3 set of complete dentures that are variable in occlusion only. during the study, dissatisfied participants can leave it. each set will be inserted for 1month in 5 participant randomly. the participants will be examined in two stages, after a day and after a week. at the end of month the questionaire will be filled out and the pressure under the mandibular denture base will be measured with the pressure sensors. then the second and third denture will be inserted simultaneously.


Eligibility criteria:
inclusion criteria: * edentulous patients * at least 3 month ago the latest teeth was extracted * ideal jaw relation * signing the informed consent exclusion criteria: * uncontrolled systemic disease * mentally problem * dissatisfaction for keeping on the study

Keywords: lingualized occlusion complete denture occlusion fully bilateral balanced occlusion patient satisfaction of complete denture
a randomized multicenter study to compare two types of transplant in adult patients with hematologic malignancies

Conditions: Hematologic Malignancies

Summary: this is an open-label, prospective, observational, multicenter, randomized study to compare the efficacy between unrelated umbilical cord blood transplantation (ucbt) and hla-haploidentical related hematopoietic stem cell transplantation ,after myeloablative conditioning for adult patients with hematologic malignancies.


Eligibility criteria:
inclusion criteria: 1. age: subjects ≥ 18 and ≤ 55 years old. 2. patients without suitable matched related donor 3. diagnosed with acute leukemia or myelodysplastic syndrome in which allogeneic transplantation is considered the most potentially curative therapeutic option. 4. written consent form signed. exclusion criteria: * performance status: eastern cooperative oncology group(ecog) score \>2 * prior allogenic hematopoietic stem cell transplant * left-ventricular ejection fraction at rest \< 45%, uncontrolled arrhythmias or symptomatic heart failure. * diffusing capacity (dlco) and/or forced vital capacity (fvc) \< 39% of predicted values or symptomatic pulmonary disease * altered liver function tests (total bilirubin \> 2 mg/dl and/or alanine aminotransferase, aspartate aminotransferase , and or active hepatitis or cirrhosis. * serum creatinine \> 2 mg/dl or estimated creatinine clearance \< 50 ml/min * evidence of uncontrolled bacterial, viral or fungal infection prior to the conditioning regimen * serious diseases that prevent patients from receiving chemotherapy treatments. * concomitant neoplasms. * pregnancy or breast-feeding. * any other medical, surgical or psychiatric condition that is considered by the attending and/or medical team as a contraindication for intensive treatment
a study of incb099280 in combination with axitinib in adults with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this study is being conducted to evaluate the safety and tolerability of incb099280 in combination with axitinib and to assess the antitumor activity of incb099280 in combination with axitinib. this study will only be open in the uk and eu.


Eligibility criteria:
inclusion criteria: * histologically confirmed advanced solid tumors (protocol-defined select solid tumors) with measurable lesions per response evaluation criteria in solid tumors version 1.1 (recist v1.1) that are considered non-amenable to surgery or other curative treatments or procedures. * must have disease progression on or after treatment with at least one prior systemic chemotherapy. * eastern cooperative oncology group performance status score of 0 or 1. * life expectancy \> 12 weeks. * willingness to avoid pregnancy. exclusion criteria: * known additional malignancy that is progressing or requires active treatment. * central nervous system (cns) metastases requiring treatment and/or leptomeningeal disease. * toxicity from prior therapy that has not recovered to protocol-defined limits. * prior receipt of an anti-pd-1, anti-pd-l1, or anti-pd-l2 agent; treatment with an immune modulator (eg, ctla-4, gitr, lag3, tim3, ox40, icos, il-2, 4-1bb, car-t cell). * prior therapy with antiangiogenic small-molecule tkis targeting the vegf pathway * participation in another interventional clinical study while receiving incb099280. * impaired cardiac function or clinically significant cardiac disease. * history or evidence of interstitial lung disease including noninfectious pneumonitis. * presence of gastrointestinal conditions that may affect drug absorption. * any autoimmune disease requiring systemic treatment in the past 5 years. * diagnosis of primary immunodeficiency or receiving chronic systemic steroid therapy at a daily dose exceeding 10 mg of prednisone or equivalent. * active infection requiring systemic therapy. * history of organ transplantation, including stem cell transplantation. * receipt of systemic antibiotics within 28 days of first dose of study treatment. * probiotic usage is prohibited during screening and throughout the study treatment period. * received a live vaccine within 28 days of the planned start of study drug. * laboratory values outside the protocol-defined ranges. * inadequate organ function. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: gynecologic tract cancer ovarian cancer primary peritoneum cancer fallopian tube cancer uterine cancer cervical cancer vulvar cancer vaginal cancer clear cell histology mucinous adenocarcinoma carcinosarcoma serous adenocarcinoma neuroendocrine histology small cell histology small-molecule pdl1 inhibitor tyrosine kinase inhibitor combination therapy
the use of inpwt for management of alt flap donor site wound

Conditions: Incisional Negative Pressure Wound Therapy

Summary: primary closure or skin grafting of the donor site after harvest of a anterolateral thigh flap (alt) is associated with significant morbidity. incisional negative pressure wound therapy (npwt) may decrease complications in high-risk incisions. successful use of npwt has been reported in the treatment of alt flap donor site wounds in a retrospective observational study, but no prospective study of npwt application in the alt flap donor site has been reported. this study aims to assess the incidence of complications at alt flap donor site with an incisional npwt device, prevena™. a prospective, controlled, pair-matched study has been designed to compare the effectiveness, complication rate, and scar quality of alt flap donor site between using incisional npwt and conventional bolster dressing.

primary closure or skin grafting of the donor site after harvest of a anterolateral thigh flap (alt) is associated with significant morbidity. incisional negative pressure wound therapy (npwt) may decrease complications in high-risk incisions. successful use of npwt has been reported in the treatment of alt flap donor site wounds in a retrospective observational study, but no prospective study of npwt application in the alt flap donor site has been reported. this study aims to assessed the incidence of complications at alt flap donor site with an incisional npwt device, prevena™. a prospective, controlled, pair-matched study has been designed to compare the effectiveness, complication rate, and scar quality of alt flap donor site between using incisional npwt and conventional bolster dressing.

Eligibility criteria:
the study is designed as a prospective randomized clinical trial. this study aims to enroll patients who require a free alt flap for head and neck reconstruction. inclusion criteria are as follows: 1. the donor site of alt flap can be closed primarily. 2. age≥20 years and \<80 years 3. alt flap size measuring more than 6 cm in width 4. patients will be required to understand and be willing to participate in the trial and be able to comply with the follow-up visits exclusion criteria are as follows: 1. he donor site of alt flap can not be closed primarily. 2. uncontrolled diabetes mellitus, as measured by hba1c≥10% 3. under renal replacement therapy for more than 1 year. 4. pregnant woman

Keywords: free flap, head and neck cancer, wound care
effect of probiotics in the atopic dermatitis

Conditions: Atopic Dermatitis, Probiotics

Summary: this study was designed to evaluate the efficacy of probiotics in the treatment of atopic dermatitis. probiotics in ad patients were effective in reducing scorad index levels, but not effective in skin prick test positivity, serum il-2-4-5-6-10, tnf-α, ifn-γ, ecp, and serum total and specific ige levels.

frequently encountered in clinical practice, in the last 30 years, the prevalence of ad has rapidly increased as a result of industrialization. thus, a new wave of quests for the treatment and prevention of ad has pushed forward. for the randomized, double-blinded, and placebo-controlled study this study was designed to evaluate the efficacy of probiotics in the treatment of ad. scorad positivity index of decline rates decline rates of the probiotic group of patients after treatment and skin prick tests were higher than that of the control group. while serum levels of il-2-4-5-6-10, tnf-α, ifn-γ, ecp decreased in the probiotic group, only levels of il-2-4-5, tnf-α decreased in the control group. the ige decrease rate, the skin prick test, the serum total and specific of the probiotic group showed no difference from those of the control group. probiotics in ad patients were effective in reducing scorad index levels, but not effective in skin prick test positivity, serum il-2-4-5-6-10, tnf-α, ifn-γ, ecp, and serum total and specific ige levels.

Eligibility criteria:
inclusion criteria:scorad (scoring atopic dermatitis) index is based on medium-heavy (carr 2006). age range is 1-13 with no patient showing evidence of any other disease except the existent disease - exclusion criteria:no drug was used for 14 (fourteen) days prior to study, including antihistamines and steroids. also, no occurrence of malabsorption, such as gastrointestinal disease, was detected. -

Keywords: atopic dermatitis, probiotic, scorad index, prick tests, cytokines
combination of laparoskopic uterosacral ligament and round ligament plication, a meshless method in the surgical treatment of pelvic organ prolapse.

Conditions: Pelvic Organ Prolapse; Prolapse Uterus; Prolapse Bladder

Summary: postoperative results of a meshless method in the surgical treatment of pelvic organ prolapse; combination of laparoscopic uterosacral ligament and round ligament plication.

following the approval of the ethics committee, female patients admitted to urogynecology and gynecology outpatient clinic of zeynep kamil gynecology and child diseases education and research hospital with the complaint of prolapse of the genital organs, who do not respond or not willing to take conservative treatment and have stage 2 or higher pelvic organ prolapse according to pop-q staging system and who have completed the fertility period will be included in our study. patients age, gravida and parity of the patients, menopausal status, whether she is hysterectomized, the stage of prolapse according to pop-q and other gynecological examination findings will be recorded.patients will be asked about preoperative urinary system pathologies (voiding dysfunction, urinary incontinence, recurrent uti) and urodynamic examination will be done accordingly. prolapsus and its impact on the quality of life will be recorded preoperatively with quality of life questionnaires.at the early postoperative period and preoperatively, the duration of the operation, blood loss during the surgery, vas score , and the presence of complications will be recorded. patients will be called postoperatively for control examination at the 1st month , 6th month , 1st year and subsequently annual control will be done.objective success; stage 1 according to pop-q or no prolapse. subjective success will be accepted once the patient has no prolapse-related complaints.in the postoperative period, whether there is any change in urinary system and sexual functions will be questioned with the help of questionnaires.laparoscopic uterosacral ligament plication, fixation of pvc fascia and the combination with round ligament plication will be evaluated in terms of efficacy and reliability.

Eligibility criteria:
inclusion criteria: * female patients age between 30 to 85 * having stage 2 or higher pelvic organ prolapse according to pop-q staging system * patients who accept the surgical treatment exclusion criteria: * patients who have a gynecological malignancy * pregnant patients
an artificial intelligence algorithm for identifying gynecologic cancer patients in need of outpatient palliative care

Conditions: Advanced Malignant Female Reproductive System Neoplasm

Summary: this clinical trial tests an artificial intelligence (ai) algorithm for its ability to identify patients who may benefit from a palliative care consult for gynecologic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). a significant delay in referral to palliative care often occurs among patients with cancer. this delay can lead to poorer symptom management, decreased quality of life, and care that does not align with patient goals or values. ai algorithms are computer programs that use step-by-step procedures to solve a problem. in this trial, an ai algorithm is applied to patients' medical records in order to identify patients with a high burden of disease. information gathered from this study may help researchers learn whether this ai algorithm is useful for identifying patients who could benefit from outpatient palliative care consultation.

primary objective: i. to pilot an oncology risk prediction model to identify patients who may benefit from outpatient palliative care consultation to improve symptom management and goal-concordant care in this population. outline: patients' medical records are reviewed for consideration of palliative care consult using ai algorithm once a week (qw) for 6 months.

Eligibility criteria:
inclusion criteria: * adult patient in enhanced, electronic health record (ehr)-facilitated cancer symptom control (e2c2) with a diagnosis of advanced gynecologic malignancy (international classification of diseases \[icd\] codes c51 through c58) * weekly the reviewers will select patients by looking at patients in sorted order starting with the highest score and proceeding down the list and evaluating each patient for exclusion criteria exclusion criteria: * patients that have been seen by palliative care will be excluded for 75 days * patients under the age of 18 years * patients currently enrolled with hospice
the use of intensive care in critically ill cancer haematological patients: "trial-oh"

Conditions: Hematological Malignancies

Summary: the purpose of this study is to determine: * condition of intensive care unit (icu) admission in patients with haematological malignancies. * icu hospital and up to one year mortality. * assessment of post icu burden and health related quality at 90-d and 1 year.

1. to identify prognostic factors of short and medium term mortality, by underlining the respective weights of organ dysfunction and characteristics of underlined malignancy 2. evaluate the health related quality of life of intensive care survivors(sf36) 3. impact of intensive care on families burden (hads, ies). 4. assess clinicians' satisfaction ( intensivists, haematologists and intensive care nurses) in relation to medical decision-making. 5. establish the relevance of antifungal treatments.

Eligibility criteria:
inclusion criteria: * hematological malignancies * hospitalization in icu * age \>= 18 years exclusion criteria: * patients who have already participated to trial-oh

Keywords: leukemia lymphoma bone-marrow transplant neutropenia acute respiratory failure mechanical ventilation post icu burden icu triage dialysis septic shock
effect of inhaled albuterol in pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: the purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (pah) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient pulmonary vasodilation.


Eligibility criteria:
inclusion criteria: * a mean pulmonary artery pressure \>25mmhg, pulmonary vascular resistance \>3 wood/units and pulmonary arterial wedge pressure \<15mmhg, as documented by right heart catheterization within the last 3 years * regular use of oral pulmonary vasodilators exclusion criteria: * presence of chronic respiratory disease (as documented by prior lung imaging and pulmonary function tests), cardiovascular disease (as documented by prior echocardiography and/or left heart catheterization), thromboembolic pah (as documented by pulmonary angiography) * women of childbearing potential who do not use accepted birth- control measures * pregnant and breast-feeding women * respiratory infection within 4 weeks of testing * a systemic systolic arterial bp\> 150 and/or diastolic arterial bp\>100 on the experiment day * a resting o2 saturation of \< 90% * current smoking * bmi \>35 kg/m2 and/or a diagnosis of obstructive sleep apnea * use of inhaled or intravenous pulmonary vasodilators